期刊
EUROPEAN JOURNAL OF HEART FAILURE
卷 24, 期 6, 页码 927-943出版社
WILEY
DOI: 10.1002/ejhf.2493
关键词
Biomarkers; Remodeling; Cells; Tissue
资金
- Spanish Ministry of Science, Innovation and Universities Institute of Health Carlos III (ISCIII) [PI18/01469, PI21/00946, CB16/11/00403, CB16/11/00483]
- European Regional Development Funds
- European Commission [2019-848109-2]
- European Research Council [ERC CoG 818715]
- ERC-PoC Megfib
- National Medical Research Council of Singapore (NMRC) [NMRC/STaR/0022/2014, MOH-000280]
- Health Research Council of New Zealand [02/152, 08/070, 11/1070]
- National Heart Foundation of New Zealand
- New Zealand Lotteries Grant Board
- Foundation for Research, Science and Technology
- Christchurch Heart Institute Trust
- Netherlands Heart Foundation [2017-21, 2017-11, 2018-30, 2020B005]
- leDucq Foundation
- Deutsche Forschungsgemeinschaft [KFO311, TRR267, TTR 219, TRR 1470]
- Karolinska Institutet, the Swedish Research Council [523-2014-2336]
- Swedish Heart Lung Foundation [20150557, 20190310]
- Stockholm County Council [20170112, 20190525]
Cardiac remodelling refers to changes in the structure and function of the heart over time. Adverse remodelling can lead to heart failure, while reverse remodelling indicates a better prognosis. Remodelling affects various components of cardiac tissue and can be reflected through circulating biomarkers. Although there are different biomarkers that can provide insights into cardiac remodelling, most have not been used in clinical practice.
Cardiac remodelling refers to changes in left ventricular structure and function over time, with a progressive deterioration that may lead to heart failure (HF) development (adverse remodelling) or vice versa a recovery (reverse remodelling) in response to HF treatment. Adverse remodelling predicts a worse outcome, whilst reverse remodelling predicts a better prognosis. The geometry, systolic and diastolic function and electric activity of the left ventricle are affected, as well as the left atrium and on the long term even right heart chambers. At a cellular and molecular level, remodelling involves all components of cardiac tissue: cardiomyocytes, fibroblasts, endothelial cells and leucocytes. The molecular, cellular and histological signatures of remodelling may differ according to the cause and severity of cardiac damage, and clearly to the global trend toward worsening or recovery. These processes cannot be routinely evaluated through endomyocardial biopsies, but may be reflected by circulating levels of several biomarkers. Different classes of biomarkers (e.g. proteins, non-coding RNAs, metabolites and/or epigenetic modifications) and several biomarkers of each class might inform on some aspects on HF development, progression and long-term outcomes, but most have failed to enter clinical practice. This may be due to the biological complexity of remodelling, so that no single biomarker could provide great insight on remodelling when assessed alone. Another possible reason is a still incomplete understanding of the role of biomarkers in the pathophysiology of cardiac remodelling. Such role will be investigated in the first part of this review paper on biomarkers of cardiac remodelling.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据